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nor paracetamol or aspirin). There were a majority of “stoppers”
even among those who previously received celecoxib (53.4%).
The proportion of patients with long term COX-2 treatment (3
months or over) was higher in the “continuers” group (23.9%
vs. 13.7%; p < 0.001). Conversely, patients with history of stroke
(4.2% vs. 2.6%; p = 0.026) or coronary heart disease (14.7%
vs. 11.5%; p = 0.015) and with a higher risk of gastrointestinal
events (50.7% vs. 43.2%; p < 0.0001) were in greater propor-
tion in the “stoppers” group. Finally, the percentage of NSAID
treated patients receiving a proton pump inhibitor raised sub-
stantially from 37.1% to 72.0% (p < 0.001) between the two
periods. CONCLUSIONS: French GPs reacted in a non selective
way, making little difference between rofecoxib and celecoxib,
and between cardiovascular and gastrointestinal risks. This
unexpected behaviour may be interpreted as a concern toward a
reduction of any kind of risk and not only those targeted by the
withdrawal decision.
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OBJECTIVES: Chronic low-back pain related to osteoarthritic
changes of the lumbar spine has a signiﬁcant economic impact
on health care budgets worldwide. Anterior-Lumbar-Interbody-
Fusion (ALIF) surgery can be an effective treatment option after
non-operative therapy fails. Frequently, the affected vertebrae are
fused together using bone (autograft) from patient’s hip, which
requires additional surgery and leads to increased co-morbidity,
blood loss, infection rate, and pelvic instability. We assessed the
cost-effectiveness of rhBMP-2 compared with autograft in spine
fusion surgery over two years from a health care payer’s per-
spective in Germany and UK. METHODS: An economic model
was developed to evaluate differences in the two-year results
between spine-fusion surgery with rhBMP-2 and fusion with
bone autograft. The cost and health-related quality-of-life asso-
ciated with both arms were estimated for two years after surgery.
Data were obtained from a previously published analysis of
pooled data, in which patients in the rhBMP-2 arm showed sig-
niﬁcant clinical improvements after surgery compared to stan-
dard therapy. Cost data were obtained from German-DRGs 
and UK NHS and are reported in 2005 values. RESULTS: In
Germany, signiﬁcant reduction in secondary interventions, and
better fusion rates associated with rhBMP-2 treatment resulted
in faster return to work and generated savings of €3453 per
patient for health care insurances, leading to net savings of €503
per patient. These savings offset the upfront prize of €2950 for
rhBMP-2 therapy. In the UK, the beneﬁts of use of rhBMP-2 lead
to an incremental cost-effectiveness ratio of GBP 5483/QALY
(€8039/QALY) for the NHS. CONCLUSIONS: The standard use
of rhBMP-2 in ALIF surgery lowers costs for surgically treated
patients with degenerative changes of the lumbar spine in
Germany and is a cost-effective treatment option in the UK.
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OBJECTIVES: Clinical practice guidelines have been shown 
to improve medical practice. However the place of the reps to
improve compliance with guidelines initiated by state agencies
(HAS, AFSSAPS) has not been evaluated. The study has been ini-
tiated by several pharmaceutical industries involved in research.
METHODS: Two intervention studies were used to provide evi-
dence of the effectiveness of the reps visits on the physician prac-
tice. During their visit, the reps gave a written document. The
written document was a validated and synthesized version of a
guideline initiated by state agencies. The subjects of the guide-
lines were asthma or migraine. The ﬁrst intervention study eval-
uated the physicians’ perception of the reps’ intervention. The
second study evaluated the physicians’ knowledge. For the ﬁrst
study, the study material was a questionnaire (12 questions) and
the study was conducted by phone. For the second study, the
study material was an internet based questionnaire (40 ques-
tions) which follows the content of the written document given
by the reps to the physicians. A score was constructed to evalu-
ate the level of knowledge of the physicians. RESULTS: For the
ﬁrst study: 800 physicians have been included. 81% (82%) ﬁnd
the intervention of the reps useful and 76 % (81%) legitimate
the guidelines for asthma (migraine). For the second study: 294
physicians have been included. The level of knowledge was sig-
niﬁcantly higher for asthma after the reps’ visit (16.37/14.44)
and for the physician who conserved the written document. No
signiﬁcant results were found for migraine. CONCLUSION:
The reps can be another way to diffuse the clinical practice 
guidelines.
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OBJECTIVES: Inhaled corticosteroids (ICS) are the cornerstone
of asthma-treatment. Yet, adherence with ICS-treatment is very
low. Therefore, the aim of the study was to investigate adher-
ence, in terms of persistent use, with ICS and its determinants in
asthma-patients. METHODS: The PHARMO database includes,
among others, drug-dispensing and hospital discharge records
for >2 million subjects in The Netherlands. All asthma-patients
(age <35 yrs) with a ﬁrst prescription for ICS in 1999–2002 and
≥2 prescriptions in the ﬁrst year were included in the study. Per-
sistence during the ﬁrst year was deﬁned as the number of days
from start to time of ﬁrst failure to continue renewal of the initial
ICS, and ascertained based on the method of Catalan. Potential
determinants of persistence were assessed at ICS-start and one-
year before. RESULTS: The study-cohort included 5563 new
users of single ICS and 297 of ﬁxed combined ICS. Less than
10% of patients using single ICS, and 15% of patients using
ﬁxed combined ICS were persistent at one year. Increased 
persistence with single ICS was observed with type of ICS 
(budesonide), prescriber (specialist), prior use of long-acting
beta-agonists, previous hospitalization for asthma, metered-dose
inhaler, low starting dose, and once-daily dosing regimen at start.
Decreased persistence with ﬁxed combined ICS-treatment was
found in patients having high starting dose of ICS and prior use
of antibiotics. CONCLUSIONS: Persistence with ICS-treatment
for asthma in clinical practice is low for both single and ﬁxed
combined ICS-treatment. Persistence was mainly related to
patient-factors, such as severity of disease, and to treatment-
related factors, such as once-daily dosing frequency and low dose
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at start of treatment. Patient education and precise individual
dose titration combined with once-daily dosing regimens may
improve persistence with ICS.
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OBJECTIVE: This study models the cost-effectiveness of
tiotropium versus ipratropium in a veterans population while
incorporating information on medication compliance, disease
severity, and history of health care utilization. METHODS: Elec-
tronic medical records from the Veterans Affairs (VA) Maryland
Health Care System for 2004 were analyzed. Inclusion criteria:
1) ﬁlled prescription for ipratropium in 2004; 2) pulmonary
function test (PFT) results; 3) PFT-based evidence of chronic
obstructive pulmonary disease (COPD). Hospitalizations and
emergency room (ER) visits for COPD exacerbations, COPD
severity, and medication adherence were identiﬁed via chart
review. The relative effectiveness of tiotropium was based on
published clinical trial results. The incremental cost-effectiveness
ratio (ICER) was calculated for 702 actual ipratropium patients
and 702 modeled tiotropium patients for two effects: avoided
exacerbations (ICERex) and avoided hospitalizations (ICERhos).
Sensitivity analysis was also conducted. RESULTS: The iprat-
ropium sample characteristics were: mean age of 69 years; 98
percent male; 21 percent Black; and 40 percent smokers. The dis-
tribution by severity was: mild (7%), moderate (42%), severe
(40%) and very severe (11%). The total (exacerbation-related)
ER visits and hospitalizations were 879 (171) and 462 (75),
reﬂecting the exclusion of 40 ER and 9 hospital encounters fol-
lowing missed medications. The overall ICERex and ICERhos
were $1318.38 and $4284.75. Tiotropium was dominant in very
severe patients: ICERex of −$2099.00 and ICERhos of 
−$6297.00. Tiotropium was dominant (−$4215.46) for patients
with one hospitalization and ranged from $433.29 to $117.27
for patients with one to three ER visits. The results were most
sensitive to variation in tiotropium compliance, the cost of ipra-
tropium, and the relative efﬁcacy of tiotropium. CONCLU-
SIONS: Assuming VA efﬁcacy similar to published estimates,
tiotropium is more cost-effective in patients with more severe
disease or a history of ER visits and is dominant when con-
sidering patients with very severe COPD or with a previous 
hospitalization.
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OBJECTIVES: To evaluate the use and costs of all health care
provider services among 1000 patients with chronic asthma
during a ﬁve year period. METHODS: Patients who had visited
the Pulmonary Clinics of Helsinki University Hospital during the
yrs 2000–2004 were invited to the study. The participants’
consent was obtained and a comprehensive medical history col-
lected from all health care providers who had treated the 
participant during the last 5 years. Data included all physician
recorded symptoms, signs, adverse drug effects, complications,
diagnostic test results, given treatments, and procedures as
unstructured text. Using advanced linguistic analysis methods,
we identiﬁed for each event both cost related attributes (loca-
tion, personnel, type of contact, urgency) and clinical attributes
(age, gender, BMI, smoking, lung functions, co-morbidities, and
prescribed medication) potentially explaining the differences
across their clinical outcomes. We developed a medication inde-
pendent score for the stability of asthma based on physician
recorded observations. Membership [0.1] of an asthma related
contact was deﬁned as a probability-like function P. RESULTS:
Our regression model is based on 65,698 health care contacts
explaining a signiﬁcant proportion (43%) of all direct non-
pharmacological costs of the patients. Fifty-six percent of the
contacts were asthma related. An asthma related event occurred
on average 6 times per year with an average cost of €256 (based
on average costs in Finland). Unexpectedly the use of prescrip-
tion antihistamines resulted less frequent patient interaction with
the health care system and potentially in better asthma control.
Smoking, adverse drug events, co-morbidities, existing allergy
symptoms increased asthma related expenditures signiﬁcantly.
Use of antihistamines, normal FVC in spirometry, and male
gender decreased the costs. CONCLUSIONS: This empirical
model of health care utilization can be used to explain differ-
ences in health care utilization among patients with different 
co-morbidities and different treatment protocols.
PODIUM SESSION IV: CANCER
CN1
TREATMENTS FOR METASTATIC MELANOMA: SYNTHESIS OF
EVIDENCE FROM RANDOMIZED TRIALS
Einarson TR1, Lui P1, Cashin R1, Machado M2, Corey-Lisle P3,
Hemels M4
1University of Toronto,Toronto, ON, Canada, 2Universidad de Chile,
Santiago, RM, Chile, 3Bristol-Myers Squibb, Wallingford, CT, USA,
4Bristol-Myers Squibb, Braine-L’Alleud, Belgium
OBJECTIVES: Advanced melanoma is usually fatal, with few
effective treatments. Dacarbazine (DTIC) is considered standard
therapy, but newer drugs have recently been marketed. The study
objective was to quantify success rates (Complete + Partial
response) of DTIC alone versus all other comparators in treat-
ing Stage-III (non-resectable) and Stage-IV melanoma of cuta-
neous origin. METHODS: We retrieved all head-to-head
randomized controlled trials involving dacarbazine (DTIC) and
other active drugs or multiple-drug combinations. Two review-
ers searched the literature, and compared results, with differ-
ences resolved through consensus. Success rates were combined
using random effects meta-analysis. Heterogeneity was tested
using chi-square and publication bias using funnel plots and 
the Begg-Mazumdar test. Quality was assessed using Jadad’s
method. RESULTS: We found 23 studies (3356 patients, 1966
DTIC, 1390 other treatments, average age = 52.8 ± 4.3) with
DTIC as standard treatment. Studies were generally of poor
quality; 2 scored “high” quality and 21 scored “low” quality.
Heterogeneity was non-signiﬁcant (chi-square = 24.63, P = 0.32),
suggesting combinability. Funnel plots were not abnormal and
the Begg-Mazumdar test was non-signiﬁcant (tau = −0.13, P =
0.38), indicating no publication bias. DTIC success rate was
14.9%. All other treatments combined were somewhat superior
to DTIC alone (OR = 1.31, CI95%:1.06–1.61). Average survival
time was 7.5 ± 2.0 months for DTIC and 8.7 ± 3.6 months for
all others. Adjunct therapy [DTIC+additional drug(s)] was supe-
